Business Context and Reporting Period
This Form 8-K was filed by Pavmed Inc. on June 15, 2020. The company is an emerging growth company incorporated in Delaware, with principal executive offices in New York. Its common stock and warrants trade on The Nasdaq Stock Market LLC under the symbols PAVM, PAVMZ, and PAVMW.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding a specific corporate event and does not contain financial statements or performance metrics.
Material Changes
The material change reported is a strategic personnel appointment. On June 15, 2020, Stanley Lapidus, founder and former Chairman and CEO of Exact Sciences, joined Lucid Diagnostics Inc., a majority-owned subsidiary of Pavmed Inc., as a Strategic Advisor.
Outlook and Management Commentary
According to the press release incorporated by reference, Mr. Lapidus will assist the subsidiary with the following strategies:
- Commercial strategy
- Regulatory strategy
- Clinical trial strategy
- Capital markets strategy
The filing notes that the information furnished under Item 7.01 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the exact scope of Stanley Lapidus's advisory role and any compensation arrangements via the attached press release (Exhibit 99.1).
- Confirm the ownership percentage Pavmed Inc. holds in Lucid Diagnostics Inc.
- Review recent financial filings (10-K or 10-Q) for actual financial performance data, as this 8-K contains none.